A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02413229|
Recruitment Status : Completed
First Posted : April 9, 2015
Results First Posted : December 6, 2018
Last Update Posted : December 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|Plaque Psoriasis||Drug: DSXS1411 Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||151 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis|
|Actual Study Start Date :||April 2015|
|Actual Primary Completion Date :||September 14, 2015|
|Actual Study Completion Date :||January 29, 2016|
DSXS applied once a day for a total of 28 days.
DSXS (Taro Pharmaceuticals Inc.)
Other Name: Active
Placebo Comparator: Placebo
Placebo (vehicle) applied once a day for a total of 28 days.
Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Other Name: vehicle
- Clinical Response of Success [ Time Frame: 28 Days ]The proportion of patients in each treatment group that have clinical success at Day 28, which is defined by a Investigator's Global Assessment score of 0 or 1.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02413229
|Study Chair:||Novum Pharmaceutical Research Services||http://www.novumprs.com/contact|